Allied Market Research
Loading...
Cart
0
New
New Allied Market Research

Biobanking Market by Specimen Type (Blood Products, Solid Tissue, Nucleic Acid, and Cell Lines), Type of Biobank (Population-based Biobanks and Disease-oriented Biobanks), Ownership (National/Regional Agencies, Nonprofit Organization, University, and Private Organization), and Application (Therapeutic and Research): Global Opportunity Analysis and Industry Forecast, 2020–2027

A02463
Pages: 245
Oct 2020 | 8883 Views
 
Author(s) : Surabhi Pandey, Apoorva Srivastava , Onkar Sumant
Tables: 140
Charts: 22
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Biobanking Market

Request Now !

The global biobanking market was valued at $37.93 billion in 2019, and is estimated to reach $57.67 billion by 2027, growing at a CAGR of 4.6% from 2020 to 2027. 

Biobanking is a procedure to collect and preserve biological materials that can be further used for diagnosis, biodiversity studies, and research. The major factors that drive the growth of the global biobanking market include rise in funding support by private & government organizations. Furthermore, increase in incidence of chronic disease propels the market growth. However, ethical and legal issues related to biobanking restrict the market growth.

Biobanking-Market-2020-2027

Get more information on this report : Request Sample Pages

 

The outbreak of the COVID-19 pandemic has brought to the forefront the significance of biobanks across the globe. Hence, rapid establishment of a COVID-19 biobank are being witnessed across the world to prospectively collect research biospecimens and corresponding clinical and patient provided data from COVID-19 patients with confirmed infection with the novel SARS-CoV-2 virus to enable high-quality research. For instance, the Minister of Health and Welfare, NHRI Biobank was assigned to establish a COVID-19 biobank in early February 2020 to collect blood samples of COVID-19 patients for Taiwan researchers and industries in an emergent way. All these factors are anticipated to impact the biobanking market in the future. Hence, the outbreak of the pandemic positively impacted the growth of the biobanking market.

Several chronic diseases such as cancer, cardiovascular diseases, neurological disorders, and immunological disorders cannot be treated using conventional therapies, as they lead to harmful side effects. The risk of these side effects could be reduced by integrating it with stem cell therapy, which acts as a healing agent to reduce the damage caused by treatment doses. As per the statistics by the National Cancer Institute, around 9.5 million individuals were reported to be suffering from cancer in the U.S. in 2019, and this number is expected to increase to 19 million in 2024. This is expected to increase the need of cord blood for therapeutic purposes, thus fueling the biobanking market growth. 

The samples from biobanks are used for various purposes such as research, therapeutics, clinical trials, and drug development. This has led to increase in funding by many nonprofit and government organizations for the establishment of more public storage banks. For instance, more than 200 clinical trials are funded by the National Institutes of Health and are being carried out in the U.S. alone. In addition, in October 2017, National Institutes of Health granted $2.1 million to the UK ME/CFS Biobank, which represents a huge investment in biomedical research. Thus, rise in funds for biobanks is expected to fuel the market growth. 

Increase in genomic research activities acts as a key factor that contributes toward the market growth. Furthermore, government is making many initiatives to support regenerative medicine research, which is expected to boost the biobanking market growth. Increase has been witnessed in the demand for cost-effective drug delivery & development, which accelerates the market growth. Advancement in the regenerative medicine is anticipated to further drive the growth of the market. Increase in research collaboration and changes in the biobanking operations act as the key driving forces of the global biobanking market.

Biobanking Market
By Specimen type

Your browser does not support the canvas element.

Blood products holds the dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Biobanking Market Segmentation

The global biobanking market is segmented into specimen type, type of biobank, ownership, application, and region. Depending on specimen type, the market is categorized into blood products, solid tissue, cell lines, nucleic acid, and others. On the basis of ownership, it is divided into national/regional agencies, nonprofit organization, university, and private organization. The applications covered in the study include therapeutic and research. By type of biobank, the market is bifurcated into population and disease-oriented biobank. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Segment review

On the basis of specimen type, the blood product segment was the major revenue contributor in 2019, and is anticipated to continue this trend during the forecast period. This is attributed to surge in prevalence of hematological diseases and rise in accidents. 

By application, the therapeutic segment is expected to grow at a highest CAGR, owing to increase in incidence of chronic diseases and advancements in regenerative medicines. 

Biobanking Market
By Application

Your browser does not support the canvas element.

Therapeutic segment is projected as one of the most lucrative segments.

Get more information on this report : Request Sample Pages

Asia-Pacific presents lucrative opportunities for key players operating in the biobanking market, owing to increase in population coupled with presence of large geriatric population base. In addition, rise in healthcare expenditure and developing guidelines are expected to propel the market growth in the region.

Some of the major companies that operate in the global market for biobanks are BioIVT & Elevating Science, Geneticist Inc, Firalis S.A., AMS biotechnology Ltd. (AMSBIO LLC), and US Biolab Corporation, Inc., ProteoGenex, Inc., Cureline, Inc., Bay Biosciences LLC, CTI Biotech, and Boca Biolistics.

Biobanking Market
By Region

2027
Europe 
North America
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 6.1% during 2020-2027

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the global biobanking market, with current trends and future estimations to elucidate the imminent investment pockets.
  • Quantitative analysis from 2019 to 2027 is expected to enable the stakeholders to capitalize on prevailing market opportunities.
  • Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
  • Extensive analysis is conducted by closely following key product positioning and monitoring the top contenders within the biobanking market framework.

Key Market Segments

By Specimen Type

  • Blood Products
  • Solid Tissue
  • Cell Lines
  • Nucleic Acid
  • Others 

By Application

  • Therapeutic
  • Research

By Type of Biobank

  • Population-based Biobanks
  • Disease-oriented Biobanks 

By Ownership

  • National/Regional Agencies
  • Nonprofit Organization
  • University
  • Private Organization

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.1.Research methodology

1.1.1.Secondary research
1.1.2.Primary research
1.1.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top player positioning

3.3.Porter’s five forces analysis
3.4.Market dynamics

3.4.1.Drivers, restraints, and opportunity
3.4.2.Drivers

3.4.2.1.Rise in funds for biobanks
3.4.2.2.Increase in R&D activities for application of biobank specimens
3.4.2.3.Surge in prevalence of fatal chronic diseases

3.4.3.Restraints

3.4.3.1.Legal and ethical issues of biobanking
3.4.3.2.Lack of awareness toward biobanking

3.4.4.Opportunity

3.4.4.1.High growth potential in developing countries

3.5.Impact of COVID-19 on biobanking market

3.5.1.Overview
3.5.2.Impact analysis
3.5.3.List of 10 largest biobanks across the globe

CHAPTER 4:BIOBANKING MARKET, BY SPECIMEN TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Blood products

4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Solid tissues

4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Cell lines

4.4.1.Key market trends and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Nucleic acid

4.5.1.Key market trends and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

4.6.Others

4.6.1.Key market trends and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country

CHAPTER 5:BIOBANKING MARKET, BY TYPE OF BIOBANK

5.1.Overview

5.1.1.Market size and forecast

5.2.Population-based biobanks

5.2.1.Key market trends and opportunities
5.2.2.Market size and forecast, by region
5.2.3.Market analysis, by country

5.3.Disease-oriented biobanks

5.3.1.Key market trends and opportunities
5.3.2.Market size and forecast, by region
5.3.3.Market analysis, by country

CHAPTER 6:BIOBANKING MARKET, BY OWNERSHIP

6.1.Overview

6.1.1.Market size and forecast

6.2.National/regional agencies

6.2.1.Key market trends and opportunities
6.2.2.Market size and forecast, by region
6.2.3.Market analysis, by country

6.3.Nonprofit organization

6.3.1.Key market trends and opportunities
6.3.2.Market size and forecast, by region
6.3.3.Market analysis, by country

6.4.Universities

6.4.1.Key market trends and opportunities
6.4.2.Market size and forecast, by region
6.4.3.Market analysis, by country

6.5.Private organization

6.5.1.Key market trends and opportunities
6.5.2.Market size and forecast, by region
6.5.3.Market analysis, by country

CHAPTER 7:BIOBANKING MARKET, BY APPLICATION

7.1.Overview

7.1.1.Market size and forecast

7.2.Therapeutic

7.2.1.Key market trends and opportunities
7.2.2.Market size and forecast, by region
7.2.3.Market analysis, by country

7.3.Research

7.3.1.Key market trends and opportunities
7.3.2.Market size and forecast, by region
7.3.3.Market analysis, by country

CHAPTER 8:BIOBANKING MARKET, BY REGION

8.1.Overview

8.1.1.Market size and forecast

8.2.North America

8.2.1.Key market trends, growth factors, and opportunities
8.2.2.North America market size and forecast, by country

8.2.2.1.U.S. biobanking market size and forecast, by specimen type
8.2.2.2.U.S. biobanking market size and forecast, by type of biobank
8.2.2.3.U.S. biobanking market size and forecast, by ownership
8.2.2.4.U.S. biobanking market size and forecast, by application
8.2.2.5.Canada biobanking market size and forecast, by specimen type
8.2.2.6.Canada biobanking market size and forecast, by type of biobank
8.2.2.7.Canada biobanking market size and forecast, by ownership
8.2.2.8.Canada biobanking market size and forecast, by application
8.2.2.9.Mexico biobanking market size and forecast, by specimen type
8.2.2.10.Mexico biobanking market size and forecast, by type of biobank
8.2.2.11.Mexico biobanking market size and forecast, by ownership
8.2.2.12.Mexico biobanking market size and forecast, by application

8.2.3.North America market size and forecast, by specimen type
8.2.4.North America market size and forecast, by type of biobank
8.2.5.North America biobanking market size and forecast, by ownership
8.2.6.North America biobanking market size and forecast, by application

8.3.Europe

8.3.1.Key market trends, growth factors, and opportunities
8.3.2.Europe market size and forecast, by country

8.3.2.1.Germany biobanking market size and forecast, by specimen type
8.3.2.2.Germany biobanking market size and forecast, by type of biobank
8.3.2.3.Germany biobanking market size and forecast, by ownership
8.3.2.4.Germany biobanking market size and forecast, by application
8.3.2.5.France biobanking market size and forecast, by specimen type
8.3.2.6.France biobanking market size and forecast, by type of biobank
8.3.2.7.France biobanking market size and forecast, by ownership
8.3.2.8.France biobanking market size and forecast, by application
8.3.2.9.UK biobanking market size and forecast, by specimen type
8.3.2.10.UK biobanking market size and forecast, by type of biobank
8.3.2.11.UK biobanking market size and forecast, by ownership
8.3.2.12.UK biobanking market size and forecast, by application
8.3.2.13.Italy biobanking market size and forecast, by specimen type
8.3.2.14.Italy biobanking market size and forecast, by type of biobank
8.3.2.15.Italy biobanking market size and forecast, by ownership
8.3.2.16.Italy biobanking market size and forecast, by application
8.3.2.17.Spain biobanking market size and forecast, by specimen type
8.3.2.18.Spain biobanking market size and forecast, by type of biobank
8.3.2.19.Spain biobanking market size and forecast, by ownership
8.3.2.20.Spain biobanking market size and forecast, by application
8.3.2.21.Rest of Europe biobanking market size and forecast, by specimen type
8.3.2.22.Rest of Europe biobanking market size and forecast, by type of biobank
8.3.2.23.Rest of Europe biobanking market size and forecast, by ownership
8.3.2.24.Rest of Europe biobanking market size and forecast, by application

8.3.3.Europe market size and forecast, by specimen type
8.3.4.Europe market size and forecast, by type of biobank
8.3.5.Europe biobanking market size and forecast, by ownership
8.3.6.Europe biobanking market size and forecast, by application

8.4.Asia-Pacific

8.4.1.Key market trends, growth factors, and opportunities
8.4.2.Asia-Pacific market size and forecast, by country

8.4.2.1.Japan biobanking market size and forecast, by specimen type
8.4.2.2.Japan biobanking market size and forecast, by type of biobank
8.4.2.3.Japan biobanking market size and forecast, by ownership
8.4.2.4.Japan biobanking market size and forecast, by application
8.4.2.5.China biobanking market size and forecast, by specimen type
8.4.2.6.China biobanking market size and forecast, by type of biobank
8.4.2.7.China biobanking market size and forecast, by ownership
8.4.2.8.China biobanking market size and forecast, by application
8.4.2.9.India biobanking market size and forecast, by specimen type
8.4.2.10.India biobanking market size and forecast, by type of biobank
8.4.2.11.India biobanking market size and forecast, by ownership
8.4.2.12.India biobanking market size and forecast, by application
8.4.2.13.Australia biobanking market size and forecast, by specimen type
8.4.2.14.Australia biobanking market size and forecast, by type of biobank
8.4.2.15.Australia biobanking market size and forecast, by ownership
8.4.2.16.Australia biobanking market size and forecast, by application
8.4.2.17.Rest of Asia-Pacific biobanking market size and forecast, by specimen type
8.4.2.18.Rest of Asia-Pacific biobanking market size and forecast, by type of biobank
8.4.2.19.Rest of Asia-Pacific biobanking market size and forecast, by ownership
8.4.2.20.Rest of Asia-Pacific biobanking market size and forecast, by application

8.4.3.Asia-Pacific market size and forecast, by specimen type
8.4.4.Asia-Pacific market size and forecast, by type of biobank
8.4.5.Asia-Pacific biobanking market size and forecast, by ownership
8.4.6.Asia-Pacific biobanking market size and forecast, by application

8.5.LAMEA

8.5.1.Key market trends, growth factors, and opportunities
8.5.2.LAMEA market size and forecast, by country

8.5.2.1.Brazil biobanking market size and forecast, by specimen type
8.5.2.2.Brazil biobanking market size and forecast, by type of biobank
8.5.2.3.Brazil biobanking market size and forecast, by ownership
8.5.2.4.Brazil biobanking market size and forecast, by application
8.5.2.5.South Africa biobanking market size and forecast, by specimen type
8.5.2.6.South Africa biobanking market size and forecast, by type of biobank
8.5.2.7.South Africa biobanking market size and forecast, by ownership
8.5.2.8.South Africa biobanking market size and forecast, by application
8.5.2.9.Saudi Arabia biobanking market size and forecast, by specimen type
8.5.2.10.Saudi Arabia biobanking market size and forecast, by type of biobank
8.5.2.11.Saudi Arabia biobanking market size and forecast, by ownership
8.5.2.12.Saudi Arabia biobanking market size and forecast, by application
8.5.2.13.Rest of LAMEA biobanking market size and forecast, by specimen type
8.5.2.14.Rest of LAMEA biobanking market size and forecast, by type of biobank
8.5.2.15.Rest of LAMEA biobanking market size and forecast, by ownership
8.5.2.16.Rest of LAMEA biobanking market size and forecast, by application

8.5.3.LAMEA market size and forecast, by specimen type
8.5.4.LAMEA market size and forecast, by type of biobank
8.5.5.LAMEA biobanking market size and forecast, by ownership
8.5.6.LAMEA biobanking market size and forecast, by application

CHAPTER 9:COMPANY PROFILES

9.1.AMS BIOTECHNOLOGY LTD. (AMSBIO LLC)

9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio

9.2.BAY BIOSCIENCES LLC

9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio

9.3.BIOIVT & ELEVATING SCIENCE

9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Key strategic moves and developments

9.4.BOCA BIOLISTICS

9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio

9.5.CTI BIOTECH

9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Product portfolio

9.6.CURELINE, INC.

9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio

9.7.FIRALIS S.A.

9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio

9.8.GENETICIST INC.

9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio

9.9.PROTEOGENEX, INC.

9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio

9.10.US BIOLAB CORPORATION, INC.

9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio

LIST OF TABLES

TABLE 01.BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 02.BIOBANKING MARKET REVENUE FOR BLOOD PRODUCTS, BY REGION, 2019–2027 ($MILLION)
TABLE 03.BIOBANKING MARKET REVENUE FOR SOLID TISSUE, BY REGION, 2019–2027 ($MILLION)
TABLE 04.BIOBANKING MARKET REVENUE FOR CELL LINES, BY REGION, 2019–2027 ($MILLION)
TABLE 05.BIOBANKING MARKET REVENUE FOR NUCLEIC ACID SAMPLES, BY REGION, 2019–2027 ($MILLION)
TABLE 06.BIOBANKING MARKET REVENUE FOR OTHERS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 08.POPULATION-BASED BIOBANKING MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 09.DISEASE-ORIENTED BIOBANKING MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 10.BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 11.BIOBANKING MARKET REVENUE FOR NATIONAL/REGIONAL AGENCY, BY REGION, 2019–2027 ($MILLION)
TABLE 12.BIOBANKING MARKET REVENUE FOR NONPROFIT ORGANIZATION, BY REGION, 2019–2027 ($MILLION)
TABLE 13.BIOBANKING MARKET REVENUE FOR UNIVERSITY, BY REGION, 2019–2027 ($MILLION)
TABLE 14.BIOBANKING MARKET REVENUE FOR PRIVATE ORGANIZATION, BY REGION, 2019–2027 ($MILLION)
TABLE 15.BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 16.BIOBANKING MARKET REVENUE FOR THERAPEUTIC APPLICATION, BY REGION, 2019–2027 ($MILLION)
TABLE 17.BIOBANKING MARKET REVENUE FOR RESEARCH APPLICATION, BY REGION, 2019–2027 ($MILLION)
TABLE 18.BIOBANKING MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 19.NORTH AMERICA BIOBANKING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 20.U.S. BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 21.U.S. BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 22.U.S. BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 23.U.S. BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 24.CANADA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 25.CANADA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 26.CANADA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 27.CANADA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 28.MEXICO BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 29.MEXICO BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 30.MEXICO BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 31.MEXICO BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 32.NORTH AMERICA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 33.NORTH AMERICA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 34.NORTH AMERICA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 35.NORTH AMERICA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 36.EUROPE BIOBANKING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 37.GERMANY BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 38.GERMANY BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 39.GERMANY BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 40.GERMANY BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 41.FRANCE BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 42.FRANCE BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 43.FRANCE BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 44.FRANCE BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 45.UK BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 46.UK BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 47.UK BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 48.UK BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 49.ITALY BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 50.ITALY BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 51.ITALY BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 52.ITALY BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 53.SPAIN BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 54.SPAIN BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 55.SPAIN BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 56.SPAIN BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 57.REST OF EUROPE BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 58.REST OF EUROPE BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 59.REST OF EUROPE BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 60.REST OF EUROPE BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 61.EUROPE BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 62.EUROPE BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 63.EUROPE BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 64.EUROPE BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 65.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 66.JAPAN BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 67.JAPAN BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 68.JAPAN BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 69.JAPAN BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 70.CHINA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 71.CHINA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 72.CHINA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 73.CHINA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 74.INDIA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 75.INDIA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 76.INDIA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 77.INDIA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 78.AUSTRALIA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 79.AUSTRALIA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 80.AUSTRALIA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 81.AUSTRALIA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 82.REST OF ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 83.REST OF ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 84.REST OF ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 85.REST OF ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 86.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 87.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 88.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 89.ASIA-PACIFIC BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 90.LAMEA BIOBANKING MARKET REVENUE, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 91.BRAZIL BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 92.BRAZIL BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 93.BRAZIL BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 94.BRAZIL BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 95.SOUTH AFRICA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 96.SOUTH AFRICA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 97.SOUTH AFRICA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 98.SOUTH AFRICA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 99.SAUDI ARABIA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 100.SAUDI ARABIA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 101.SAUDI ARABIA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 102.SAUDI ARABIA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 103.REST OF LAMEA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 104.REST OF LAMEA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 105.REST OF LAMEA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 106.REST OF LAMEA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 107.LAMEA BIOBANKING MARKET REVENUE, BY SPECIMEN TYPE, 2019–2027 ($MILLION)
TABLE 108.LAMEA BIOBANKING MARKET REVENUE, BY TYPE OF BIOBANK, 2019–2027 ($MILLION)
TABLE 109.LAMEA BIOBANKING MARKET REVENUE, BY OWNERSHIP, 2019–2027 ($MILLION)
TABLE 110.LAMEA BIOBANKING MARKET REVENUE, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 111.AMSBIO: COMPANY SNAPSHOT
TABLE 112.AMSBIO: PRODUCT CATEGORY
TABLE 113.AMSBIO: PRODUCT PORTFOLIO
TABLE 114.BAY BIOSCIENCES: COMPANY SNAPSHOT
TABLE 115.BAY BIOSCIENCES: PRODUCT CATEGORY
TABLE 116.BAY BIOSCIENCES: PRODUCT PORTFOLIO
TABLE 117.BIOIVT: COMPANY SNAPSHOT
TABLE 118.BIOIVT: OPERATING SEGMENTS
TABLE 119.BIOIVT: PRODUCT PORTFOLIO
TABLE 120.BOCA BIOLISTICS: COMPANY SNAPSHOT
TABLE 121.BOCA BIOLISTICS: OPERATING SEGMENTS
TABLE 122.BOCA BIOLISTICS: PRODUCT PORTFOLIO
TABLE 123.CTI BIOTECH: COMPANY SNAPSHOT
TABLE 124.CTI BIOTECH: SERVICE PORTFOLIO
TABLE 125.CURELINE: COMPANY SNAPSHOT
TABLE 126.FIRALIS: OPERATING SEGMENTS
TABLE 127.CURELINE: SERVICE PORTFOLIO
TABLE 128.FIRALIS: COMPANY SNAPSHOT
TABLE 129.FIRALIS: OPERATING SEGMENTS
TABLE 130.FIRALIS: SERVICE PORTFOLIO
TABLE 131.GENETICIST: COMPANY SNAPSHOT
TABLE 132.HAMILTON COMPANY: SEGMENTS
TABLE 133.GENETICIST: PRODUCT PORTFOLIO
TABLE 134.PROTEOGENEX: COMPANY SNAPSHOT
TABLE 135.PROTEOGENEX: OPERATING SEGMENTS
TABLE 136.PROTEOGENEX: PRODUCT PORTFOLIO
TABLE 137.US BIOLAB: COMPANY SNAPSHOT
TABLE 138.US BIOLAB: OPERATING SEGMENTS
TABLE 139.US BIOLAB: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GLOBAL BIOBANKING MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP PLAYER POSITIONING, 2019
FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
FIGURE 05.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06.HIGH THREAT OF NEW ENTRANTS
FIGURE 07.MODERATE THREAT OF SUBSTITUTION
FIGURE 08.MODERATE COMPETITIVE RIVALRY
FIGURE 09.DRIVERS, RESTRAINTS, AND OPPORTUNITY
FIGURE 10.BIOBANKING MARKET REVENUE FOR BLOOD PRODUCTS, BY COUNTRY, 2019–2027 (%)
FIGURE 11.BIOBANKING MARKET REVENUE FOR SOLID TISSUE, BY COUNTRY, 2019–2027 (%)
FIGURE 12.BIOBANKING MARKET REVENUE FOR CELL LINES, BY COUNTRY, 2019–2027 (%)
FIGURE 13.BIOBANKING MARKET REVENUE FOR NUCLEIC ACID SAMPLES, BY COUNTRY, 2019–2027 (%)
FIGURE 14.BIOBANKING MARKET REVENUE FOR OTHERS, BY COUNTRY, 2019–2027 (%)
FIGURE 15.POPULATION-BASED BIOBANKING MARKET REVENUE, BY COUNTRY, 2019–2027 (%)
FIGURE 16.DISEASE-ORIENTED BIOBANKING REVENUE, BY COUNTRY, 2019–2027 (%)
FIGURE 17.BIOBANKING MARKET REVENUE FOR NATIONAL/REGIONAL AGENCY, BY COUNTRY, 2019–2027 (%)
FIGURE 18.BIOBANKING MARKET REVENUE FOR NONPROFIT ORGANIZATION, BY COUNTRY, 2019–2027 (%)
FIGURE 19.BIOBANKING MARKET REVENUE FOR UNIVERSITY, BY COUNTRY, 2019–2027 (%)
FIGURE 20.BIOBANKING MARKET REVENUE FOR PRIVATE ORGANIZATION, BY COUNTRY, 2019–2027 (%)
FIGURE 21.BIOBANKING MARKET REVENUE FOR THERAPEUTIC APPLICATION, BY COUNTRY, 2019–2027 (%)
FIGURE 22.BIOBANKING MARKET REVENUE FOR RESEARCH APPLICATION, BY COUNTRY, 2019–2027 (%)

 
 

The biobanking market gained prominence in 2019, and is expected to witness a significant rise in the near future. This is attributed to rise in incidence of fatal diseases, increase in funding by government for biobank research projects, and surge in awareness toward the benefits of biobank specimens such as cord blood for human health. However, certain limitations such as ethical and legal issues related to biobanking are expected to restrain the market growth. 

Biobanking plays an integral role in advancing biomedical and translational research through the collection and preservation of biological samples, such as blood, tissues, and nucleic acids, which are subsequently made available for use in research to discover disease-relevant biomarkers; this is further used for diagnosis, prognosis, and predicting drug responses. Furthermore, increase in number of research activities acts as a major driver of the global market. 

Moreover, rise in government funding for regenerative medicine, stem cell therapeutics, and cell & gene therapy is supporting research activities, which, in turn, is anticipated to boost the demand for biobanking products and services. Furthermore, increase in trend of cord blood banking is expected to supplement the market growth, globally. Future prospects including advancements in orthopedic procedures with the use of stem cells are expected to augment market growth for biobanking.

North America dominates the biobanking market, due to the presence of numerous large-scale biobanks in the U.S., while Asia-Pacific is expected to grow at the highest growth rate during the forecast period, due to increase in government investment in biomedical and biotechnology industries. 

 
PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of Biobanking market is $37.93 billion in 2019.

A. The forcast period for Biobanking market is 2020 to 2027

A. The market value of Biobanking market in 2027 is $57.67 billion.

A. The base year is 2019 in Biobanking market

A. Top companies such as,BioIVT & Elevating Science, Geneticist Inc, Firalis S.A., AMS biotechnology Ltd. (AMSBIO LLC), and US Biolab Corporation, Inc. held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. In specimen type segment blood product is the most influencing segment. This is attributed to surge in prevalence of hematological diseases and rise in accidents.By application, the global biobanking market is bifurcated into therapeutic and research.

A. The major factor that fuels the growth of the global Biobanking market includes rise in funds for biobanks, increase in R&D activities for application of biobank specimens, and surge in prevalence of fatal chronic diseases drive the growth of the global biobank market.However, legal and ethical issues of biobanking such as confidentiality as well as sample collection laws & regulations and lack of awareness toward biobanking are expected to hamper the market growth.

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the emerging countries. This is due to improvement in health awareness, development in healthcare infrastructure, and rise in number of hospitals equipped with advanced medical facilities.

A. Biobanking is a biorepository for receiving and storing biological specimens such as plant, animal, and microbe; which can be later used for supporting many types of contemporary research associated with genomics, healthcare research, medical care, and drug discovery.

A. Biobanks can give researchers access to data representing a large number of people. Samples in biobanks and the data derived from those samples can often be used by multiple researchers for cross purpose research studies. Furthermore, it permits large-scale analysis for individuation of specific disease biomarkers, which will facilitate the development of personalized medicine.

Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research Allied Market Research

RELATED TAGS

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Biobanking Market

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $9,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts